Cinqair Side Effects Center

Last updated on RxList: 8/8/2022
Cinqair Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Cinqair?

Cinqair (reslizumab) injection is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

What Are Side Effects of Cinqair?

Common side effects of Cinqair include:

  • mouth and throat pain.

Cinqair may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • dizziness,
  • nauseated,
  • lightheadedness,
  • itching,
  • shortness of breath, and
  • swelling in your face

Get medical help right away, if you have any of the symptoms listed above.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheartedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Cinqair

The recommended dosage regimen of Cinqair is 3 mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes.

What Drugs, Substances, or Supplements Interact with Cinqair?

Cinqair may interact with other drugs. Tell your doctor all medications and supplements you use.

Cinqair During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant before receiving Cinqair. It is unknown if Cinqair passes into breast milk or if it could affect a nursing infant. Consult your doctor before breastfeeding.

Additional Information

Our Cinqair (reslizumab) injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Asthma is a chronic respiratory disease. See Answer
Cinqair Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during or shortly after the injection. Tell your caregiver if you feel dizzy, nauseated, light-headed, itchy, short of breath, or if you have swelling in your face.

Common side effects may include:

  • sore throat; or
  • muscle pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What Is Asthma? Symptoms, Causes, and Treatments See Slideshow
Cinqair Professional Information


The following adverse reactions are discussed in other sections of the labeling:

  • Anaphylaxis [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Overall, 2195 subjects received at least 1 dose of CINQAIR. The data described below reflect exposure to CINQAIRin 1611 patients with asthma, including 1120 exposed for up to 16 weeks, 1006 exposed for 6 months, 759 exposed for 1 year, and 249 exposed for longer than 2 years. The above referenced safety exposure for CINQAIR is derived from placebo-controlled studies ranging from 15 to 52 weeks in duration (CINQAIR 0.3 mg/kg and 3 mg/kg [n=1131]and placebo [n=730]) and 480 new CINQAIR 3 mg/kg exposures (previously on placebo) from a single open-label extension study (n=1051). While a lower dose of CINQAIR 0.3 mg/kg (n=103) was included in a clinical trial, 3mg/kg is the only recommended dose [see DOSAGE AND ADMINISTRATION]. Of the 1611 patients, 1596 received the3 mg/kg dose, 1028 of which were in the placebo-controlled studies. In the placebo-controlled asthma studies, the population studied was 12 to 76 years of age, 62% female, and 73% white. While subjects aged 12 to 17 years were included in these trials, CINQAIR is not approved for use in this age group [see Use In Specific Populations].

Serious adverse reactions that occurred in placebo-controlled studies in more than 1 subject and in a greater percentage of subjects treated with CINQAIR (n=1131) than placebo (n=730) included anaphylaxis (3 subjects vs. 0subjects, respectively). The 3 subjects who experienced anaphylaxis were discontinued from the clinical studies [see WARNINGS AND PRECAUTIONS]. Malignancy also occurred more commonly in patients treated with CINQAIR than placebo (0.6% and 0.3%, respectively) [see WARNINGS AND PRECAUTIONS].

Adverse reactions that occurred at greater than or equal to 2% incidence and more commonly than in the placebo group included 1 event: Oropharyngeal pain (2.6% vs. 2.2%).

CPK Elevations And Muscle-Related Adverse Reactions

Elevated baseline creatine phosphokinase (CPK) was more frequent in patients randomized to CINQAIR (14%)versus placebo (9%). Transient CPK elevations in patients with normal baseline CPK values were observed more frequently with CINQAIR (20%) versus placebo (18%) during routine laboratory assessments. CPK elevations >10 xULN, regardless of baseline CPK value, were 0.8% in the CINQAIR group compared to 0.4% in the placebo group.CPK elevations >10 x ULN were asymptomatic and did not lead to treatment discontinuation.

Myalgia was reported in 1% (10/1028) of patients in the CINQAIR 3 mg/kg group compared to 0.5% (4/730) of patients in the placebo group. On the day of infusion, musculoskeletal adverse reactions were reported in 2.2% and1.5% of patients treated with CINQAIR 3 mg/kg and placebo, respectively. These reactions included (but were not limited to) musculoskeletal chest pain, neck pain, muscle spasms, extremity pain, muscle fatigue, and musculoskeletal pain.


As with all therapeutic proteins, there is a potential for immunogenicity. In placebo-controlled studies, a treatment-emergent anti-reslizumab antibody response developed in 53/983 (5.4%) of CINQAIR-treated patients (3 mg/kg). in the long-term, open-label study, treatment-emergent anti-reslizumab antibodies were detected in 49/1014 (4.8%) ofCINQAIR-treated (3 mg/kg) asthma patients over 36 months. The antibody responses were of low titer and often transient. Neutralizing antibodies were not evaluated. There was no detectable impact of the antibodies on the clinical pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of CINQAIR [see CLINICAL PHARMACOLOGY]. Product-specific IgE antibodies were not detected in patients who reported anaphylactic reactions.

The data reflect the percentage of patients whose test results were positive for antibodies to reslizumab in specific assays. The observed incidence of antibody response is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to reslizumab with the incidence of antibodies to other products may be misleading.


No formal clinical drug interaction studies have been performed with CINQAIR.

Read the entire FDA prescribing information for Cinqair (Reslizumab for Intravenous Infusion)

© Cinqair Patient Information is supplied by Cerner Multum, Inc. and Cinqair Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors